Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | STAT1 | P42224 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27547148 | 0.86 | KDM4E (0.47) | KDM4EPKMPIK3CDP2RX7LMNA | |
| SCHEMBL9361993 | 0.79 | KDM4E (0.48) | KDM4EPKMPIK3CDP2RX7LMNA | |
| SCHEMBL11368864 | 0.79 | KDM4E (0.48) | KDM4EPKMP2RX7SLC6A3MEN1 | |
| Acetic Acid SCHEMBL31405463 | 0.78 | KDM4E (0.47) | KDM4EPKMPIK3CDP2RX7LMNA | |
| Bromide SCHEMBL11363394 | 0.78 | KDM4E (0.47) | KDM4EPKMP2RX7SLC6A3MEN1 | |
| SCHEMBL10482490 | 0.77 | KDM4E (0.46) | KDM4EPKMPIK3CDP2RX7LMNA | |
| SCHEMBL15150557 | 0.75 | — | — | |
| SCHEMBL6870706 | 0.74 | KDM4E (0.39) | KDM4EPKMPIK3CDP2RX7LMNA | |
| SCHEMBL16541153 | 0.73 | KDM4E (0.42) | KDM4EPKMPIK3CDP2RX7LMNA | |
| SCHEMBL8683323 | 0.73 | KDM4E (0.43) | KDM4EPKMPIK3CDP2RX7LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2484688-B1 | PEPTIDE EPOXYKETONES FOR PROTEASOME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140100169-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130338057-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. | 2013-12-19 | — | — | US | disclosed |
| US-8609654-B1 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2484688-A1 | PEPTIDE EPOXYKETONES FOR PROTEASOME INHIBITION | Onyx Therapeutics, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080545-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2041158-A2 | PEPTIDE EPOXYKETONES FOR PROTEASOME INHIBITION | Proteolix, Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007149512-A2 | PEPTIDE EPOXYKETONES FOR PR0TEAS0ME INHIBITION | PROTEOLIX, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100169-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20120088762-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20130338057-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20100144648-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | KDM4E 193/4885PKM 2545/4885PIK3CD 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.